Novavax, U.S. government extend partnership

Novavax announced a modification to its existing agreement with the U.S. Department of Health and Human Services, in collaboration with the Department of Defense, to deliver up to 1.5M doses of the Novavax COVID-19 Vaccine, Adjuvanted. This agreement will maintain the U.S. public’s access to Novavax’ vaccine and support the development of smaller dose vials, strain selection in line with U.S. FDA recommendations, and a smooth transition to the commercial market. The modified agreement also includes the development of an updated vaccine in fall 2023.